Trials of arbaclofen for autism yield mixed results
Autistic children taking the drug showed improvements in some behaviors but not in their social skills.
Autistic children taking the drug showed improvements in some behaviors but not in their social skills.
Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.
This month’s newsletter takes a close look at the orphan drug program in the United States, several cannabis-based therapies and a secondary analysis of bumetanide, among other new developments in autism-related drug trials.
In this edition of Null and Noteworthy, scientists find little to be excited about in research on biomarkers for neurodevelopmental conditions.
Altered expression of TSC2 and the mTOR pathway reshape the formation of certain synapses between inhibitory and excitatory neurons in mice.
Conventional optogenetic manipulations to excite or inhibit neurons stop when the light switches off. A new approach makes the changes last.
The method yields complex organoids that more closely mimic embryonic brain development than do those cultured in other ways.
The circuit linking the prefrontal cortex and part of the thalamus is impaired in mice raised in social isolation and in mice with mutations in the FMR1 or TSC2 genes.
Data from two separate research teams suggest the cells are key to sensory hypersensitivity in fragile X syndrome.
Iama Therapeutics is hoping a new class of molecule will prove successful against an old target in autism.